Hong Kong

We analyzed the key regulations governing the hiring of foreign workers, types of work permits, and the timelines and conditions for obtaining them. Based on this data, we developed a detailed step-by-step employee relocation plan covering all stages of migration and employment formalities – from preparing documents and submitting applications to obtaining permits and integrating employees into the local work environment.

The client received a clear roadmap for relocating staff to Hong Kong, enabling the minimization of legal non-compliance risks, optimization of timelines, and efficient resource allocation. The process was structured to ensure seamless employee onboarding and compliance with all requirements of Hong Kong’s immigration and labor authorities.

The client needed to establish unified HR processes for several jurisdictions, including Hong Kong, which, despite its special status, follows the Anglo-Saxon model of employment law with flexible contractual relationships. We thoroughly studied the differences in labor regulation between the target countries, analyzed mandatory provisions and local practices, and identified potential risks when unifying procedures. Based on this data, we developed a strategy for implementing unified HR processes that take into account the requirements of each local legal system.

The client received a coordinated HR administration system adapted to the specifics of Hong Kong’s labor law and other jurisdictions. Legal and operational risks were minimized, ensuring predictability and compliance with local requirements while maintaining a unified corporate approach.

We analyzed the tax and corporate implications of the proposed structure and described the tax benefits available to the group of companies in Cyprus and Hong Kong, agreed on the optimal solution for the ownership of shares in the companies between the founders of the group and developed protection mechanisms in the event of conflict between the founders, including a set of option agreements for each of the companies that not only comply with applicable law, but are also automatically enforceable in the relevant jurisdictions.

The group of companies was successfully incorporated in Hong Kong and Cyprus taking into account tax efficiency and corporate benefits. All founders received fair and transparent mechanisms for the ownership of shares in the company, and the developed option agreements provided legal mechanisms for the founders to exit the business in case of disagreement. The company operates successfully, taking into account all legal and tax requirements.

We developed a corporate structure for companies with the participation of a nominee shareholder and registered the company in Hong Kong. After that, we supported the transfer of shares of a Hong Kong company to the capital of a UAE fund and supported the process of opening a corporate bank account in mainland China and Kazakhstan.

Launch of a turnkey business taking into account the multi-jurisdictional nature of the project.

We checked the possibility of building a settlement system that ensures the smooth fulfillment of financial obligations using cryptocurrencies – a test of the theory of the feasibility of implementing the project with the help of a company in Hong Kong.

Provided the client with an assessment of the most suitable types of licenses in the field of finance and settlements to comply with Hong Kong requirements, which allowed the client to make an effective management decision.

Development of the project, as well as project management from the idea stage to confirmation of the results of the assessment of IP objects included in biotechnological products.

Supported the transfer of IP objects as a contribution to the authorized capital, ensuring compliance with the commercial secrecy regime applicable to know-how.

We developed a business model and facilitated the establishment of a joint venture to bring pharmaceutical products to the markets of China, Hong Kong, Macau, and Taiwan.

A joint venture was established, with our legal support secured for the next three years, covering corporate governance, financing, drug registration, distribution, and clinical trials.